Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;13(3):233-40.
doi: 10.1007/s11926-011-0173-y.

Advances in glucocorticoid-induced osteoporosis

Debby den Uyl  1 , Irene E M Bultink, Willem F Lems
Affiliations
Review

Advances in glucocorticoid-induced osteoporosis

Debby den Uyl et al. Curr Rheumatol Rep. 2011 Jun.

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is one of the most important side effects of glucocorticoid use, as it leads to an increased risk of fractures. Recently, many published studies have focused on the cellular and molecular mechanisms of bone metabolism, the pathophysiology of GIOP, and the intervention options to prevent GIOP. In this review, recent advances in GIOP are summarized, particularly recent progress in our understanding of the mechanisms of GIOP resulting in improved insight that might result in the development of new treatment options in the near future.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Pathophysiology of glucocorticoid-induced effects on bone cells. BMP—bone morphogenetic protein; Dkk-1—dickkopf-1; GSK3β—glycogen synthase kinase 3β; OPG—osteoprotegerin; PPAR—peroxisome proliferator-activated receptor; RANKL—receptor activator for nuclear factor-κB ligand; Runx2—runt-related protein 2
See this image and copyright information in PMC

References

    1. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–899. doi: 10.1359/JBMR.040134. - DOI - PubMed
    1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–787. doi: 10.1007/s001980200108. - DOI - PubMed
    1. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002;61:32–36. doi: 10.1136/ard.61.1.32. - DOI - PMC - PubMed
    1. Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17:105–108. doi: 10.1007/s00198-005-1923-3. - DOI - PubMed
    1. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202–211. doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. - DOI - PubMed

MeSH terms

Substances